Plasma metabolic signature of cardiovascular and cerebrovascular diseases from a large cohort study

doi:10.3969/j.issn.1674-8115.2022.03.001

Abstract

Abstract: Objective

·To explore the metabolic differences for the occurrence and development of cardiovascular and cerebrovascular diseases, the study performed the plasma metabolic analysis by nano-enhanced laser desorption ionization-mass spectrometry (NELDI-MS) on a large cohort.

Methods

·People were enrolled from general population establishment and follow-up cohort in Pudong New Area, Shanghai. Plasma samples were prospectively collected from 14 419 cohort people who met the criteria from February to August 2019. All the cohort people were divided into coronary heart disease (CHD) group (n=1 608), stroke group (n=461), cardiovascular and cerebrovascular diseases (CHD+stroke) group (n=145) and the control group (n=12 205). The plasma metabolic fingerprints (PMFs) of the enrolled samples were collected by NELDI-MS and then analyzed by statistical analysis for identifying the typical metabolic biomakers in patients with stroke, patients with CHD, and patients with both CHD and stroke.

Results

·Three hundred and forty-five metabolic signal peaks were extracted as PMFs. Six metabolic biomarkers with differential regulations were identified as the potential risk factor for cardiovascular and cerebrovascular diseases respectively by mass spectrometry data analysis. Further, the six metabolic biomarkers were mapped into the altered ketone body and fatty acid metabolism clusters. In the cluster of ketone body metabolism, the intensities of amidosulfonic acid, acetoacetic acid and methylmalonic acid were significantly increased in patients with CHD, but significantly decreased in patients with stroke and cardiovascular cerebrovascular diseases. In the cluster of fatty acid metabolism, the intensities of glucose, galacturonic acid and α-linolenic acid were significantly decreased in patients with cardiovascular and cerebrovascular diseases, but significantly increased in patients with stroke. According to the above six metabolic biomakers, three related metabolic pathways were identified in the cluster of ketone body metabolism, and two related metabolic pathways were identified in the cluster of fatty acid metabolism.

Conclusion

·The novel solid-phase MS approach used in this study has realized the high-efficiency collection of PMFs in a large cohort of people. Six plasma metabolic biomarkers with differential regulation are identified in cohort people with cardiovascular and cerebrovascular diseases, shedding light on the molecular pathological mechanisms of cardiovascular and cerebrovascular diseases from metabolic perspectives. It is expected to provide metabolic clues for the pathogenesis of cardiovascular and cerebrovascular diseases.

Key words: cardiovascular and cerebrovascular disease, coronary heart disease (CHD), stroke, plasma metabolic fingerprint (PMF), metabolomics, biomaker

CLC Number:

R540.4

ZHANG Mengji, HUANG Lin, LI Zheng, MA Zhuoran, WEI Lin, YUAN Ancai, HU Liuhua, ZHANG Wei, QIAN Kun, PU Jun. Plasma metabolic signature of cardiovascular and cerebrovascular diseases from a large cohort study[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(3): 259-266.

Figures/Tables 5

TrendMD

References 23

1	国家心血管病中心. 中国心血管健康与疾病报告2019[M]. 北京: 科学出版社, 2020.
2	XU W, LIN J X, GAO M, et al. Rapid computer-aided diagnosis of stroke by serum metabolic fingerprint based multi-modal recognition[J]. Adv Sci Weinheim Baden Wurttemberg Ger, 2020, 7(21): 2002021.
3	ZHANG M J, HUANG L, YANG J, et al. Ultra-fast label-free serum metabolic diagnosis of coronary heart disease via a deep stabilizer[J]. Adv Sci Weinheim Baden Wurttemberg Ger, 2021, 8(18): e2101333.
4	HUANG L, WANG L, HU X M, et al. Machine learning of serum metabolic patterns encodes early-stage lung adenocarcinoma[J]. Nat Commun, 2020, 11(1): 3556.
5	REIF B, ASHBROOK S E, EMSLEY L, et al. Solid-state NMR spectroscopy [J]. Nat Rev Methods Primers, 2021, 1: 2.
6	YUAN M, KREMER D M, HUANG H, et al. Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC-MS/MS[J]. Nat Protoc, 2019, 14(2): 313-330.
7	ZHENG F J, ZHAO X J, ZENG Z D, et al. Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography-mass spectrometry[J]. Nat Protoc, 2020, 15(8): 2519-2537.
8	HUANG L, WAN J J, WEI X, et al. Plasmonic silver nanoshells for drug and metabolite detection[J]. Nat Commun, 2017, 8(1): 220.
9	SU H Y, LI X X, HUANG L, et al. Plasmonic alloys reveal a distinct metabolic phenotype of early gastric cancer[J]. Adv Mater Deerfield Beach Fla, 2021, 33(17): e2007978.
10	YANG J, WANG R, HUANG L, et al. Urine metabolic fingerprints encode subtypes of kidney diseases[J]. Angewandte Chemie Int Ed Engl, 2020, 59(4): 1703-1710.
11	KHERA A V, KATHIRESAN S. Genetics of coronary artery disease: discovery, biology and clinical translation[J]. Nat Rev Genet, 2017, 18(6): 331-344.
12	KATHIRESAN S, SRIVASTAVA D. Genetics of human cardiovascular disease[J]. Cell, 2012, 148(6): 1242-1257.
13	LACAZE P, SEBRA R, RIAZ M, et al. Genetic variants associated with inherited cardiovascular disorders among 13 131 asymptomatic older adults of European descent[J]. NPJ Genom Med, 2021, 6(1): 51.
14	MOKOU M, LYGIROU V, VLAHOU A, et al. Proteomics in cardiovascular disease: recent progress and clinical implication and implementation[J]. Expert Rev Proteom, 2017, 14(2): 117-136.
15	KHAN A, SHIN M S, JEE S H, et al. Global metabolomics analysis of serum from humans at risk of thrombotic stroke[J]. Anal, 2020, 145(5): 1695-1705.
16	任繁栋, 丁筱雪, 蔡芳, 等. 基于超高效液相色谱-高分辨质谱联用技术研究冠心病及冠心病合并2型糖尿病患者代谢特征[J]. 分析化学, 2020, 48(01): 49-56.
17	HOLEČEK M. Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements[J]. Nutr Metab, 2018, 15: 33.
18	KOLB H, KEMPF K, RÖHLING M, et al. Ketone bodies: from enemy to friend and guardian angel[J]. BMC Med, 2021, 19(1): 313.
19	ZHANG L, LIU C D, JIANG Q Y, et al. Butyrate in energy metabolism: there is still more to learn[J]. Trends Endocrinol Metab TEM, 2021, 32(3): 159-169.
20	YURISTA S R, CHONG C R, BADIMON J J, et al. Therapeutic potential of ketone bodies for patients with cardiovascular disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2021, 77(13): 1660-1669.
21	KATHARINA L. New roles for gluconeogenesis in vertebrates[J]. Curr Opin Syst Biol, 2021, 28: 100389.
22	PACKER M, ANKER S D, BUTLER J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15): 1413-1424.
23	YURISTA S R, CHONG C R, BADIMON J J, et al. Therapeutic potential of ketone bodies for patients with cardiovascular disease: jacc state-of-the-art review[J]. J Am Coll Cardiol, 2021, 77(13): 1660-1669.

Item	Stroke （n=461）	CHD （n=1 608）	Stroke+CHD （n=145）	Control （n=12 205）	P value
Gender/n （%）					0.000
Male	220 （47.7）	587 （36.5）	50 （34.5）	5 861 （48.0）
Female	241 （52.3）	1 021 （63.5）	95 （65.5）	6 344 （52.0）
Age/year	69.0 （58.0‒90.0）	69.0 （55.0‒89.0）	72.0 （59.0‒87.0）	67.0 （39.0‒96.0）	0.000
Body fat percentage/%	24.7 （16.7‒34.3）	24.6 （15.8‒50.0）	24.5 （17.7‒32.4）	24.3 （12.70‒49.92）	0.000
Height/cm	160.0 （126.0‒183.0）	160.0 （100.0‒184.0）	159.0 （143.0‒175.0）	162.0 （123.0‒193.0）	0.000
Weight/kg	63.7 （40.7‒101.8）	63.0 （36.0‒120.0）	63.0 （39.8‒89.0）	64.0 （34.7.0‒117.5）	0.206
Hypertension/n （%）	114 （24.7）	451 （28.0）	31 （21.4）	5 459 （44.7）	0.000
Diabetes/n （%）	342 （74.2）	1 280 （79.6）	111 （76.6）	10 351 （84.8）	0.000
Hyperlipidemia/n （%）	346 （75.1）	1 311 （81.5）	97 （66.9）	11 280 （92.4）	0.000

Item	Stroke （n=461）	CHD （n=1 608）	Stroke+CHD （n=145）	Control （n=12 205）	P value
Gender/n （%）					0.000
Male	220 （47.7）	587 （36.5）	50 （34.5）	5 861 （48.0）
Female	241 （52.3）	1 021 （63.5）	95 （65.5）	6 344 （52.0）
Age/year	69.0 （58.0‒90.0）	69.0 （55.0‒89.0）	72.0 （59.0‒87.0）	67.0 （39.0‒96.0）	0.000
Body fat percentage/%	24.7 （16.7‒34.3）	24.6 （15.8‒50.0）	24.5 （17.7‒32.4）	24.3 （12.70‒49.92）	0.000
Height/cm	160.0 （126.0‒183.0）	160.0 （100.0‒184.0）	159.0 （143.0‒175.0）	162.0 （123.0‒193.0）	0.000
Weight/kg	63.7 （40.7‒101.8）	63.0 （36.0‒120.0）	63.0 （39.8‒89.0）	64.0 （34.7.0‒117.5）	0.206
Hypertension/n （%）	114 （24.7）	451 （28.0）	31 （21.4）	5 459 （44.7）	0.000
Diabetes/n （%）	342 （74.2）	1 280 （79.6）	111 （76.6）	10 351 （84.8）	0.000
Hyperlipidemia/n （%）	346 （75.1）	1 311 （81.5）	97 （66.9）	11 280 （92.4）	0.000

[1]	LIANG Cunyu, ZHAO Qian, SONG Ning, MEN Li, CHEN Qingjie, CHU Junkun, PU Jun, LI Xiaomei, YANG Yining. Evaluation of the management effect of "Internet+"-based wearable ECG devices in coronary heart disease patients undergoing PCI [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(3): 275-281.
[2]	JIANG Huiru, LI Zheng, MA Zhuoran, WEI Lin, YUAN Ancai, HU Liuhua, CHEN Xiaoyu, GUO Yunyue, ZHANG Wei, PU Jun. Baseline characteristics and lifestyle factors of single and co-morbidity of cardio-cerebrovascular diseases in Shanghai Community Elderly Cohort [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(3): 282-289.
[3]	Jiyu HAN, Yanhong WANG, Daqian WAN. Research progress and development trend of lower extremity exoskeleton rehabilitation robot [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 241-246.
[4]	Xu-guang CHEN, Sheng-yi SHI, Lan HU, Yu CHEN, Yi-ming LU, Jing YE. Evaluative value of plasma fibrin degradation product in early prognosis of patients with hemorrhagic stroke [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 612-616.
[5]	Xiu-ying LIU, Rui-fang LAN. Correlation between quantitative electroencephalogram features and CT perfusion imaging parameters in acute ischemic stroke [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 62-65.
[6]	LIU Yi-sheng1, ZHAN Yan-li2, PAN Hui1, YIN Jia-wen1, HU Yue1, CAI Xue-li2#, LIU Jian-ren1#. Comparison of outcomes after thrombectomy in patients with embolic stroke of undetermined source and cardiogenic stroke [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1270-1276.
[7]	XU Jing-han, HE Xin-wei, LI Qiang, BAO Guan-shui. Study on the prognosis of intravenous thrombolysis in patients with ischemic strokethyroid-related hormones and antibodies [J]. , 2020, 40(4): 478-.
[8]	HUANG Ting-ting, LI Yan, ZHANG Yue-man, ZHOU Na-ying, FAN Ren-hui, LI Pei-ying. Two-photon in vivo imaging of blood brain barrier injury in the ultra-early stage of cerebral ischemic stroke [J]. , 2019, 39(9): 998-.
[9]	ZHUANG Mei-ting, HE Xin-wei, ZHAO Rong, YIN Jia-wen, HU Yue, LIU Jian-ren. Correlation between plasma brain natriuretic peptide and functional outcome after intravenous thrombolysis in patients with acute ischemic stroke [J]. , 2019, 39(9): 1065-.
[10]	HE Hong1, 2, LIU Yi-sheng1, ZHAO Rong1, LI Ge-fei1, SHI Yan-hui1, LI Yi3, LIU Jian-ren1. Impact of multiple thrombectomy on outcomes of patients with acute ischemic stroke [J]. , 2019, 39(7): 764-.
[11]	ZHANG Cui-ping, OUYANG Xiao-chun, YU Xiao-li, XIONG Wen-juan, WANG Yan-qiu, MA Yao. Relationship between glomerular filtration rate and acute ischemic stroke in middle-aged and elderly population [J]. , 2019, 39(1): 65-.
[12]	HU Yue, HE Xin-wei, LIU Yi-sheng, ZHAO Rong, LIU Jian-ren. Application of mechanical thrombectomy in the patients with wake-up stroke [J]. , 2018, 38(9): 1128-.
[13]	LIANG Dan-dan, LI Yi-tao, ZHENG Xiao-jiao, CHEN Tian-lu. Advance in full-functional software of metabolomics [J]. , 2018, 38(7): 805-.
[14]	HUANG Jin-guo1, ZHANG Hai-nan1, CHEN Zi-qing1*, YANG Li-na2, GUO Shu-juan1, TAO Sheng-ce1. Metabolomics study of the effect of arsenic trioxide on hepatocellular carcinoma cell line HepG2 [J]. , 2018, 38(10): 1145-.
[15]	LI Jing, LIU Si, LEI He-hua, WANG Yu-lan, TANG Hui-ru. Gender dependence of metabolomic phenotypes for human saliva using ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry [J]. , 2017, 37(8): 1079-.